Switch theme
Sign up to access all valuation multiples
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
2015
169
LTM Revenue $4.1M
LTM EBITDA -$204M
-$24.3M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Keros Therapeutics has a last 12-month revenue of $4.1M and a last 12-month EBITDA of -$204M.
In the most recent fiscal year, Keros Therapeutics achieved revenue of $3.5M and an EBITDA of -$186M.
Keros Therapeutics expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Keros Therapeutics valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $0.2M | $3.5M | XXX | XXX | XXX |
| Gross Profit | n/a | n/a | XXX | XXX | XXX |
| Gross Margin | NaN% | NaN% | XXX | XXX | XXX |
| EBITDA | -$152M | -$186M | XXX | XXX | XXX |
| EBITDA Margin | -100779% | -5234% | XXX | XXX | XXX |
| Net Profit | -$105M | -$153M | XXX | XXX | XXX |
| Net Margin | -69324% | -4310% | XXX | XXX | XXX |
| Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Keros Therapeutics's stock price is $13.
Keros Therapeutics has current market cap of $517M, and EV of -$24.3M.
See Keros Therapeutics trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| -$24.3M | $517M | XXX | XXX | XXX | XXX | $-4.89 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Keros Therapeutics has market cap of $517M and EV of -$24.3M.
Keros Therapeutics's trades at -6.0x LTM EV/Revenue multiple, and 0.1x LTM EBITDA.
Analysts estimate Keros Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Keros Therapeutics and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | -$24.3M | XXX | XXX | XXX |
| EV/Revenue | -6.8x | XXX | XXX | XXX |
| EV/EBITDA | 0.1x | XXX | XXX | XXX |
| P/E | -2.8x | XXX | XXX | XXX |
| P/E/Growth | n/a | XXX | XXX | XXX |
| EV/FCF | 0.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpKeros Therapeutics's NTM/LTM revenue growth is 77%
Keros Therapeutics's revenue per employee for the last fiscal year averaged $21K, while opex per employee averaged $1.3M for the same period.
Over next 12 months, Keros Therapeutics's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Keros Therapeutics's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Keros Therapeutics and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 2251% | XXX | XXX | XXX | XXX |
| EBITDA Margin | -5234% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 22% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | -5158% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $21K | XXX | XXX | XXX | XXX |
| Opex per Employee | $1.3M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1148% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 4891% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 6004% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Keros Therapeutics acquired XXX companies to date.
Last acquisition by Keros Therapeutics was XXXXXXXX, XXXXX XXXXX XXXXXX . Keros Therapeutics acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Keros Therapeutics founded? | Keros Therapeutics was founded in 2015. |
| Where is Keros Therapeutics headquartered? | Keros Therapeutics is headquartered in United States of America. |
| How many employees does Keros Therapeutics have? | As of today, Keros Therapeutics has 169 employees. |
| Who is the CEO of Keros Therapeutics? | Keros Therapeutics's CEO is Dr. Jasbir Seehra, PhD. |
| Is Keros Therapeutics publicy listed? | Yes, Keros Therapeutics is a public company listed on NAS. |
| What is the stock symbol of Keros Therapeutics? | Keros Therapeutics trades under KROS ticker. |
| When did Keros Therapeutics go public? | Keros Therapeutics went public in 2020. |
| Who are competitors of Keros Therapeutics? | Similar companies to Keros Therapeutics include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Keros Therapeutics? | Keros Therapeutics's current market cap is $517M |
| What is the current revenue of Keros Therapeutics? | Keros Therapeutics's last 12-month revenue is $4.1M. |
| What is the current EBITDA of Keros Therapeutics? | Keros Therapeutics's last 12-month EBITDA is -$204M. |
| What is the current EV/Revenue multiple of Keros Therapeutics? | Current revenue multiple of Keros Therapeutics is -6.0x. |
| What is the current EV/EBITDA multiple of Keros Therapeutics? | Current EBITDA multiple of Keros Therapeutics is 0.1x. |
| What is the current revenue growth of Keros Therapeutics? | Keros Therapeutics revenue growth between 2023 and 2024 was 2251%. |
| Is Keros Therapeutics profitable? | Yes, Keros Therapeutics is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
